Income Statement Monte Rosa Therapeutics, Inc.
Stocks
GLUE
US61225M1027
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
21:00:00 02/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 10.50 USD | -6.75% |
|
-10.79% | -33.04% |
| 10-01 | Monte Rosa Therapeutics Announces Positive Data From GFORCE-1 Phase 1 Study Evaluating MRT-8102 | CI |
| 10-01 | Monte Rosa Therapeutics, Inc. - Special Call |
| Fiscal Period: December | 2019 (USD) | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|---|---|
Revenues | - | - | - | 75.62M | 124M | ||
Total Revenues | - | - | - | 75.62M | 124M | ||
Cost of Goods Sold, Total | - | - | - | 113M | 134M | ||
Gross Profit | - | - | - | -37.24M | -10.03M | ||
Selling General & Admin Expenses, Total | 15.73M | 35.12M | 39.94M | 43.87M | 44.18M | ||
R&D Expenses | 57.16M | 77.26M | 103M | - | - | ||
Other Operating Expenses, Total | 72.88M | 112M | 143M | 43.87M | 44.18M | ||
Operating Income | -72.88M | -112M | -143M | -81.11M | -54.21M | ||
Interest Expense, Total | - | - | - | - | - | ||
Interest And Investment Income | 46K | 3.76M | 9.33M | 10.57M | 12.94M | ||
Net Interest Expenses | 46K | 3.76M | 9.33M | 10.57M | 12.94M | ||
Currency Exchange Gains (Loss) | -162K | 10K | -930K | 416K | 1.48M | ||
Other Non Operating Income (Expenses) | -960K | - | - | - | - | ||
EBT, Excl. Unusual Items | -73.96M | -109M | -135M | -70.13M | -39.78M | ||
Gain (Loss) On Sale Of Investments | - | - | -131K | - | - | ||
Gain (Loss) On Sale Of Assets | - | 109K | 24K | - | 59K | ||
EBT, Incl. Unusual Items | -73.96M | -109M | -135M | -70.13M | -39.72M | ||
Income Tax Expense | - | - | 338K | 2.57M | -1.1M | ||
Earnings From Continuing Operations | -73.96M | -109M | -135M | -72.7M | -38.63M | ||
Net Income to Company | -73.96M | -109M | -135M | -72.7M | -38.63M | ||
Net Income - (IS) | -73.96M | -109M | -135M | -72.7M | -38.63M | ||
Net Income to Common Incl Extra Items | -73.96M | -109M | -135M | -72.7M | -38.63M | ||
Net Income to Common Excl. Extra Items | -73.96M | -109M | -135M | -72.7M | -38.63M | ||
Per Share Items | |||||||
Net EPS - Basic | -2.96 | -2.3 | -2.63 | -0.98 | -0.46 | ||
Basic EPS - Continuing Operations | -2.96 | -2.3 | -2.63 | -0.98 | -0.46 | ||
Basic Weighted Average Shares Outstanding | 25M | 47.23M | 51.4M | 73.91M | 83.07M | ||
Net EPS - Diluted | -2.96 | -2.3 | -2.63 | -0.98 | -0.46 | ||
Diluted EPS - Continuing Operations | -2.96 | -2.3 | -2.63 | -0.98 | -0.46 | ||
Diluted Weighted Average Shares Outstanding | 25M | 47.23M | 51.4M | 73.91M | 83.07M | ||
Normalized Basic EPS | -1.85 | -1.44 | -1.64 | -0.59 | -0.3 | ||
Normalized Diluted EPS | -1.85 | -1.44 | -1.64 | -0.59 | -0.3 | ||
Supplemental Items | |||||||
EBITDA | -70.75M | -109M | -137M | -72.99M | -45.85M | ||
EBITA | -72.88M | -112M | -143M | -81.11M | -54.21M | ||
EBIT | -72.88M | -112M | -143M | -81.11M | -54.21M | ||
EBITDAR | -68.45M | -99.82M | -128M | -62.54M | -36.63M | ||
Effective Tax Rate - (Ratio) | - | - | -0.25 | -3.66 | 2.76 | ||
Current Domestic Taxes | - | - | - | - | -1.1M | ||
Total Current Taxes | - | - | - | - | -1.1M | ||
Normalized Net Income | -46.22M | -67.88M | -84.32M | -43.83M | -24.86M | ||
Non-Cash Pension Expense | 0 | 19K | 198K | 174K | 140K | ||
Supplemental Operating Expense Items | |||||||
General and Administrative Expenses | 15.73M | 26.3M | 30.48M | 33.42M | 34.96M | ||
Research And Development Expense From Footnotes | 57.16M | 85.06M | 111M | 122M | 142M | ||
Net Rental Expense, Total | 2.3M | 8.82M | 9.46M | 10.46M | 9.22M | ||
Stock-Based Comp., COGS (Total) | - | - | - | 10.63M | 10.86M | ||
Stock-Based Comp., R&D Exp. (Total) | 2.61M | 5.58M | 8.94M | - | - | ||
Stock-Based Comp., G&A Exp. (Total) | 2.59M | 6.08M | 7.73M | 7.5M | 8M | ||
Total Stock-Based Compensation | 5.2M | 11.66M | 16.67M | 18.13M | 18.86M |
- Stock Market
- Stocks
- GLUE Stock
- Financials Monte Rosa Therapeutics, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
